Skip to main content
Quest Diagnostics

The AlzMatch Study: Remote Plasma Acquisition to Pre-screen for Preclinical Alzheimer’s Disease Trials

Clinical Trials on Alzheimer's Disease

CTAD 2022

San Francisco, CA,  November 29 - December 2, 2022

Poster presentation: The AlzMatch Study: remote plasma acquisition to pre-screen for preclinical Alzheimer's disease trials

Authors: Walter S, Raman R, Jimenez-Maggiora GA, Rissma RA, Rafii M, Molina-Henry D, Grill J, Karlawish J, Langford O,  Bruschi S, Donohue MC, Yarasheski K, Morton J, Hahn S, Racke M, Sperling R, Cummings J, Aisen PS

Specialties: Neurology

 

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.